Introducing the Chairs at ISCO Congress 2026 – Part 1
oncodaily - International School of Clinical Oncology – ISCO shared a series of posts on Facebook, introducing the Chairs at the upcoming ISCO Congress 2026: 1. “We are delighted to welcome Prof. […]
AI Summary: The ISCO Congress 2026 has unveiled its chairpersons and session lineup, spotlighting leaders shaping the program and key scientific themes. Organizers framed the event as a platform for multidisciplinary exchange and translational oncology priorities, aiming to accelerate research-to-clinic progress while giving attendees plenty to talk about between coffee breaks.
- Leadership, training and career-development programs (4)
- Major trial takeaways across 2026 oncology congresses (4)
- Meet the ISCO 2026 Chairs and Honorees (6)
- Scientific tracks: AI, translational & cellular therapy (4)
- All Other Stories
Leadership, training and career-development programs
Major trial takeaways across 2026 oncology congresses
Meet the ISCO 2026 Chairs and Honorees
Scientific tracks: AI, translational & cellular therapy
All Other Stories
A machine learning model that uses DNA methylation patterns may help identify the origin of cancers of unknown primary
medicalxpress - A machine learning model analyzing CpG-based DNA methylation accurately predicted the origin of many different cancer types in patients with cancers of unknown primary (CUP), according to research presented at the American Association for Cancer Research …
AI Summary: A machine‑learning model trained on DNA methylation signatures can assign tissue‑of‑origin for cancers of unknown primary with promising accuracy. The approach could speed diagnosis, guide therapy choices and reduce reliance on invasive tests—handy when a tumor refuses to tell doctors where it came from.
- ctDNA and AI for treatment monitoring and early detection (3)
- Liquid biopsies and extracellular vesicles for early cancer detection (4)
- Methylation-based ML to identify cancers' tissue of origin (3)
- All Other Stories
ctDNA and AI for treatment monitoring and early detection
Liquid biopsies and extracellular vesicles for early cancer detection
Methylation-based ML to identify cancers' tissue of origin
All Other Stories
A deep learning pathomics platform may help predict response to immunotherapy in lung cancer patients
medicalxpress - A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American A…
AI Summary: Researchers developed a deep‑learning pathomics platform that analyzes routine histology to predict which lung cancer patients are likely to respond to immunotherapy. By extracting subtle morphological patterns invisible to the human eye, the tool promises to refine treatment selection and spare nonresponders unnecessary toxicity—assuming clinicians trust an algorithm more than their gut.
- AI pathomics flags immunotherapy responders in lung cancer (4)
- Challenges deploying AI in lung cancer diagnosis and care (3)
- Evolving lung cancer immunotherapy trials and biomarker debates (4)
- All Other Stories
AI pathomics flags immunotherapy responders in lung cancer
Challenges deploying AI in lung cancer diagnosis and care
Evolving lung cancer immunotherapy trials and biomarker debates
All Other Stories
Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites
medicalxpress - Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial si…
AI Summary: A new analysis shows Phase I lung cancer trials are becoming concentrated at a relatively small number of leading U.S. centers, raising concerns about geographic inequity in access to early‑phase studies. The trend could speed drug development at elite sites while leaving patients in other regions with fewer experimental options and longer travel burdens.
- Conference highlights, care models and awareness (4)
- Consolidation at top U.S. Phase I centers (3)
- Early-phase trials and next-gen therapies (4)
- All Other Stories